Advanced search
Publication Cover
CNS Oncology Volume 11, 2022 - Issue 3
Submit an article Journal homepage
2,010
Views
0
CrossRef citations to date
0
Altmetric
Case Series

First clinical experience with belzutifan in von Hippel–Lindau disease associated CNS hemangioblastoma

Andrew Dhawan1 Neurological Institute, Cleveland Clinic,Cleveland, OH44195, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5027-1277
ORCID Icon,
David M Peereboom2 Taussig Cancer Institute, Cleveland Clinic,Cleveland, OH44195, USA
&
Glen HJ Stevens1 Neurological Institute, Cleveland Clinic,Cleveland, OH44195, USA;2 Taussig Cancer Institute, Cleveland Clinic,Cleveland, OH44195, USA
Article: CNS91 | Received 19 Mar 2022, Accepted 17 Jun 2022, Published online: 12 Jul 2022

References

  • van LeeuwaardeRS, AhmadS, LinksTP, GilesRH. Von Hippel–Lindau syndrome. In: GeneReviews®.AdamMP, ArdingerHH, PagonRA ( Eds). University of Washington, WA, USA (1993).
  • LonserRR, ButmanJA, HuntoonKet al.Prospective natural history study of central nervous system hemangioblastomas in von Hippel–Lindau disease. J. Neurosurg.120(5), 1055–1062 (2014).
  • HuntoonK, ShepardMJ, LukasRV, McCutcheonIE, DanielsAB, AsthagiriAR. Hemangioblastoma diagnosis and surveillance in von Hippel–Lindau disease: a consensus statement. J. Neurosurg.136(6), 1–6 (2021).
  • KibelA, IliopoulosO, DeCaprioJA, KaelinWG. Binding of the von Hippel–Lindau tumor suppressor protein to Elongin B and C. Science269(5229), 1444–1446 (1995).
  • MaxwellPH, WiesenerMS, ChangGWet al.The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399(6733), 271–275 (1999).
  • GossageL, EisenT, MaherER. VHL, the story of a tumour suppressor gene. Nat. Rev. Cancer15(1), 55–64 (2015).
  • LinQ, CongX, YunZ. Differential hypoxic regulation of hypoxia-inducible factors 1α and 2α. Mol. Cancer Res.9(6), 757–765 (2011).
  • CourtneyKD, MaY, Diazde Leon Aet al.HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res.26(4), 793–803 (2020).
  • DeeksED. Belzutifan: first approval. Drugs81(16), 1921–1927 (2021).
  • JonaschE, DonskovF, IliopoulosOet al.Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N. Engl. J. Med.385(22), 2036–2046 (2021).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.